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Epigenetic control mechanisms are central to normal and malignant hematopoiesis. In this issue of Cancer
Cell, Deshpande and colleagues demonstrate that AF10, an interaction partner of the histonemethyltransfer-
ase DOT1L, is essential for efficient H3K79methylation, thus regulatingHOX-gene transcription and transfor-
mation in myeloid leukemia.During steady state hematopoiesis blood
components are continuously replen-
ished from a pool of multipotent hemato-
poietic stem cells. During maturation,
these precursors acquire an ever more
specialized identity that is transmitted to
their respective progeny. Phenotypic dif-
ferentiation requires a cascade of genetic
decisions that must be fixed for further
generations. In this way, unique transcrip-
tional patterns are established that trans-
late into specific function. Consequently,
epigenetic mechanisms that modify chro-
matin and DNA are pivotal for the correct
execution of this process. Accordingly,
perturbation of these activities may block
further development, leading to an accu-
mulation of rapidly dividing precursor
cells ultimately manifesting as leukemia.
It is therefore not surprising that many
alterations in DNA and chromatin modi-
fying enzymes have been identified as
driver mutations in acute leukemia.
Paradigmatic examples for an ‘‘epige-
netic’’ etiology of leukemia are the mixed
lineage leukemia (MLL) fusion proteins.
These products of chromosomal translo-
cations fuse the N terminus of the histone
methyltransferase KMT2A (alternative
name MLL) to a variety of different pro-
teins, thus replacing the original histone
H3 lysine-4 (H3K4) methyltransferase ac-
tivity of KMT2A by the particular function
of the fusion partner. It has been shown
that several of these MLL partner proteins
are members of multiprotein complexes
(Lin et al., 2010; Mueller et al., 2007,
2009; Yokoyama et al., 2010). These
contain positive transcription elongation
factor b (P-TEFb), an activity necessary
for efficient transcriptional elongation,
and/or the histone methyltransferaseDOT1L. DOT1L is the only known enzyme
catalyzing the addition of methyl groups
to lysine 79 of histone H3 (H3K79).
Although the exact biochemical mecha-
nism is still obscure, H3K79 di- and trime-
thylation is directly correlated to gene
expression. Consequently, target genes
ectopically activated by MLL fusions are
characterized by H3K79 hypermethyla-
tion. The most prominent examples for
this phenomenon are the clustered HOX-
homeoboxgenes coding for HOX-A tran-
scription factors. Besides their role in
embryogenesis, these proteins are mas-
ter regulators of hematopoiesis and are
potent hematopoietic oncoproteins in
their own right. High HOX-expression
levels are characteristic for hematopoietic
precursor cells, and HOX activity needs
to be lowered for maturation to occur.
Hence, an ectopic HOX expression,
regardless how it is achieved, will pro-
mote rapid self-renewal of immature pre-
cursors and thus foster development of
leukemia. Aberrant HOX-transcription
has been recognized as an important,
although not the sole oncogenic, driver
in MLL-induced leukemia. Because of
the conspicuous correlation of DOT1L
recruitment, H3K79 hypermethylation,
and HOX overexpression in MLL, the pre-
vious work of the Armstrong lab has been
aiming to develop DOT1L inhibitors as
potential therapeutic agents for this
particularly aggressive subtype of leuke-
mia (Bernt et al., 2011). Preclinical studies
with a small molecule DOT1L inhibitor
have been very encouraging, showing
efficient reduction of H3K79 methyla-
tion levels for key MLL-target genes,
including the HOX-cluster, accompanied
by transcriptional downregulation and aCancer Cell 26,concomitant ablation of leukemic activity.
Currently, clinical studies with a DOT1L
inhibitor in patients are under way.
In this issue of Cancer Cell, Deshpande
et al. (2014) describe experiments that
suggest that DOT1L inhibition could be
more generally effective in acute myeloid
leukemia, thus expanding this therapeuti-
cal concept beyond MLL-induced malig-
nancy. The present work concentrates
on AF10, a protein that has also been
identified as an MLL fusion partner.
AF10 is not involved in elongation stimula-
tion and does not have any known
connection to P-TEFb. Yet, AF10 has
been shown to interact directly with
DOT1L (Okada et al., 2005) andwas found
biochemically in a DOT1L containing
complex (Mohan et al., 2010), findings
that could be corroborated by the authors
in their current work. In addition, AF10 is
unique, because it is also involved in
several fusions with other partners apart
from MLL. The intriguing observation
that downregulation of HOX gene expres-
sion during normal differentiation is
accompanied by a loss of higher H3K79
methylation states, but not by a reduction
of DOT1L, suggested AF10 as a prime
candidate that may modulate locus-spe-
cific DOT1L activity (Figure 1). Indeed,
knock-down of AF10 in human leukemia
cell lines and genetic ablation of Af10 in
a conditional murine knock-out model
significantly reduced H3K79 di- and tri-
methylation, leaving H3K79 monomethy-
lation largely intact. The effect of AF10
could also be demonstrated in a purified
biochemical system. Addition of AF10
enhanced DOT1L histone methyl trans-
ferase activity significantly, generating
the testable prediction that ablation ofDecember 8, 2014 ª2014 Elsevier Inc. 781
Figure 1. The Interplay of DOT1L and AF10 in Histone Modification
AF10 interacts with the histone methyltransferase DOT1L, enhancing its cata-
lytic activity. This complex can be recruited to target loci like the HOX gene
clusters either by unknown transcription factors or by various leukemogenic
fusion proteins. These may contact DOT1L directly or through intermediate
adaptors (e.g., MLL-fusion proteins). Alternatively, AF10 itself can be directly
involved as a fusion partner. The presence of full catalytically active DOT1L/
AF10 complexes induces H3K79 di- and trimethylation that is essential for effi-
cient target transcription. Deletion of AF10 or small molecule inhibition of
DOT1L activity reduces the methylation state and prevents expression of
these genes, thus abrogating oncogenic activity. H3, histone H3; K79, lysine
79; me, methyl group.
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activity in vivo and therefore
affect foremost genes whose
transcription is particularly
dependent on higher order
H3K79 methylation like the
HOXA cluster. This was
tested with leukemia induced
by different MLL fusions.
Interestingly, the response to
AF10 depletion was graded
depending on the nature of
the MLL fusion. MLL-AF6
that recruits DOT1L indirectly
by unknown intermediates
was unable to transform in
the absence of AF10,
whereas transformation by
MLL-AF9 that can directly
bind to DOT1L was attenu-
ated but still detectable.
Providing AF10 directly by a
MLL-AF10 fusion made cells
immune against a loss of
endogenous AF10 protein,
thus strongly backing a role
for AF10 as ‘‘DOT1L
enhancer.’’ Ectopic expres-
sion of HOXA9 and its dimer-
ization partner MEIS1 com-
plemented the effects of
AF10 deletion, demonstratingthat HOX-genes are the limiting factors.
On a molecular level, a deficit of AF10
caused a dramatic reduction of H3K79
di- and trimethylation that correlated
with a drop in expression of known MLL-
fusion targets. This effect was accompa-
nied by an exit of DOT1L from chromatin
and an increase in the repressive histone
mark H3K27me3.
The fact that HOX transcription ap-
peared to be exquisitely dependent on
higher H3K79 methylation states sug-
gested that other leukemia with aberrant
HOX-expression beyond MLL rearranged
cases might also be susceptible to a
modulation of DOT1L activity. Indeed,
NUP98-NSD1 transformed cells that are
known to contain aberrantly high HOXA-
levels could not grow in the absence of
AF10 or DOT1L, and these cells were
highly sensitive toward a small molecule
DOT1L inhibitor. Overall, these results
highlight the general and particular de-782 Cancer Cell 26, December 8, 2014 ª201pendency of theHOX gene cluster regula-
tion on H3K79 methylation potentially
irrespective of the HOX-activating stim-
ulus. This makes DOT1L targeting thera-
peutics an interesting option for a
considerably wider spectrum of leukemia,
especially if other leukemias with elevated
HOX expression (e.g., acute myeloid leu-
kemia carrying NPM1 mutations) display
a similar addiction to high levels of
H3K79 methylation at the HOXA locus.
Concerns about therapeutic DOT1L
inhibition, however, have been voiced
because a complete ablation of Dot1l in
mice is lethal (Jones et al., 2008). Yet,
the obvious differential sensitivity of
various genes toward DOT1L inhibition
may provide an opportunity to avoid
unwanted side effects. The findings by
Deshpande et al. (2014) point toward a
therapeutic window of DOT1L inhibition
that may allow targeting of HOX cluster
expression without affecting general4 Elsevier Inc.transcription. Therefore, the
in vitro HOX complementa-
tion results presented here
are very promising, because
it seems that a moderate
ablation of DOT1L activity
indeed selectively affects the
HOX locus. It would be
interesting to elucidate the
molecular reason for this
behavior. If there is a special
molecular signature discrimi-
nating ‘‘DOT1L-sensitive’’
genes from others, it might
be found also for oncogenes
in solid tumors, identifying a
promising patient population
for further trials with the new
DOT1L inhibitors.REFERENCES
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